Bone Metastasis - Pipeline Review, H1 2016

Description: Bone Metastasis - Pipeline Review, H1 2016

Summary

‘Bone Metastasis - Pipeline Review, H1 2016’, provides an overview of the Bone Metastasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Metastasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Metastasis
- The report reviews pipeline therapeutics for Bone Metastasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Metastasis therapeutics and enlists all their major and minor projects
- The report assesses Bone Metastasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Metastasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Bone Metastasis Overview
Therapeutics Development
Pipeline Products for Bone Metastasis – Overview
Pipeline Products for Bone Metastasis – Comparative Analysis
Bone Metastasis – Therapeutics under Development by Companies
Bone Metastasis – Therapeutics under Investigation by Universities/Institutes
Bone Metastasis – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bone Metastasis – Products under Development by Companies
Bone Metastasis – Products under Investigation by Universities/Institutes
Bone Metastasis – Companies Involved in Therapeutics Development
Ablynx NV
Alethia Biotherapeutics Inc.
Amgen Inc.
Amura Holdings Limited
Bayer AG
Campus Technologies Freiburg GmbH
ChemoCentryx, Inc.
Deciphera Pharmaceuticals, LLC
Oncobiologics, Inc.
Oncodrone BV
Osteologix Holdings Plc
Bone Metastasis – Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
AB-25E9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADM-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-3701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile

Product Description
Mechanism of Action

R&D Progress

BKM-1644 - Drug Profile

Product Description
Mechanism of Action

R&D Progress

BKM-1740 - Drug Profile

Product Description
Mechanism of Action

R&D Progress

CCX-354 - Drug Profile

Product Description
Mechanism of Action

R&D Progress

CCX-721 - Drug Profile

Product Description
Mechanism of Action

R&D Progress

DCC-3014 - Drug Profile

Product Description
Mechanism of Action

R&D Progress

denosumab - Drug Profile

Product Description
Mechanism of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LG-1980 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NBS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OCD-155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radium Ra 223 dichloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
roneparstat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPH-203 - Drug Profile
Product Description
Mechanism of Action

R&D Progress

Bone Metastasis – Recent Pipeline Updates

Bone Metastasis - Dormant Projects

Bone Metastasis – Discontinued Products

Bone Metastasis – Product Development Milestones

Featured News & Press Releases

Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan

Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride)

Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna

Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease

Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders

Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics

Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo

Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway

May 30, 2013: Algeta Announces First Sale Of Xofigo In US

Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bone Metastasis, H1 2016

Number of Products under Development for Bone Metastasis – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Bone Metastasis – Pipeline by Ablynx NV, H1 2016

Bone Metastasis – Pipeline by Alethia Biotherapeutics Inc., H1 2016

Bone Metastasis – Pipeline by Amgen Inc., H1 2016

Bone Metastasis – Pipeline by Amura Holdings Limited, H1 2016

Bone Metastasis – Pipeline by Bayer AG, H1 2016

Bone Metastasis – Pipeline by Campus Technologies Freiburg GmbH, H1 2016

Bone Metastasis – Pipeline by ChemoCentryx, Inc., H1 2016

Bone Metastasis – Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016

Bone Metastasis – Pipeline by Oncobiologics, Inc., H1 2016

Bone Metastasis – Pipeline by Oncodrone BV, H1 2016

Bone Metastasis – Pipeline by Osteologix Holdings Plc, H1 2016

Bone Metastasis – Pipeline by R-Pharm, H1 2016

Bone Metastasis – Pipeline by Sigma-Tau S.p.A., H1 2016

Bone Metastasis – Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016

Bone Metastasis – Pipeline by Terpenoid Therapeutics, Inc., H1 2016

Bone Metastasis – Pipeline by Thar Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Bone Metastasis Therapeutics – Recent Pipeline Updates, H1 2016

Bone Metastasis – Dormant Projects, H1 2016

Bone Metastasis – Dormant Projects (Contd..1), H1 2016

Bone Metastasis – Dormant Projects (Contd..2), H1 2016

Bone Metastasis – Discontinued Products, H1 2016
List of Figures

Number of Products under Development for Bone Metastasis, H1 2016
Number of Products under Development for Bone Metastasis – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3720448/](http://www.researchandmarkets.com/reports/3720448/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bone Metastasis - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3720448/
Office Code: SCD2LP6V

Product Formats
Please select the product formats and quantity you require:

Quantity
Electronic (PDF) - Single User: [ ] USD 2000
Electronic (PDF) - Site License: [ ] USD 4000
Electronic (PDF) - Enterprisewide: [ ] USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: ____________________________
Email Address: * ________________________________________________________________
Job Title: _______________________________________________________________________
Organisation: ___________________________________________________________________
Address: _______________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________
Country: _______________________________________________________________________
Phone Number: ___________________________________________________________________
Fax Number: ______________________________________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World